EBV+ CNS LYMPHOMAS HAVE A DISTINCTIVE TUMOR MICROENVIRONMENT AND GENETIC PROFILE, WHICH IS AMENABLE TO COMBINATION 3RD PARTY EBV‐SPECIFIC CTL AND IBRUTINIB THERAPY. (12th June 2019) - Gandhi, M.K.